Company intelligence / Profile preview
AlgoSource
- Ownership
- Private
- Employees
- ~37
- Development stage
- Commercial
Overview
AlgoSource has demonstrated the effectiveness of its spirulina liquid extract in a clinical trial targeting NASH syndrome. The company is also developing AmiTher, a microalgae-based solution to reduce side effects of cancer therapies, with planned hospital-based clinical trials. Products are subject to internal/external quality controls before market release.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Microalgae-derived functional ingredientsNatural extracts
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on AlgoSource.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlgoSource.